

Spring 2017 Group Meeting Plenary II Disclosure Information

Charles Blanke, MD: No disclosures

Julie Gralow, MD: Consultant for Pfizer and Puma Biotechnology. Data Safety and Monitoring Board member for Merck, Genentech/Roche, and Novartis.

Linda House, RN, BSN, MSM : No disclosures

Susan O'Brien, MD: Consultant for TG Therapeutics, Sunesis, Pfizer, Janssen, and Gilead Sciences, Inc. Research grants from Pfizer, Acerta, Regeneron, Kite Pharmaceuticals, and Gilead.

Christopher Ryan, MD: Advisory board member for Exelixis, Eisai, and Novartis. Honoraria from Exelixis and Eisai. Research grants from Argos, Bristol-Myers Squibb, CytRx Corporation, Daiichi, Eisai, Exelixis, GSK, Janssen, MabVax, Morphotek, OSI Pharmaceuticals, Pfizer, Threshold, and Tracon

Deborah Zarin, MD: No disclosures



SWOG



Leading cancer research. **Together.**



Leading cancer research. **Together.** www.swog.org

In partnership with



News & Accomplishments

Innovations in SWOG Treatment Trials


- Julie Gralow, MD
- Susan O'Brien, MD
- Christopher Ryan, MD

Innovations in Survivorship Research

- Linda House, RN, BSN, MSM
Dr. Harry E. Hynes Lecturer

Innovations at ClinicalTrials.gov

- Deborah Zarin, MD



News & Accomplishments

PUBLIC RELEASE: 18-JAN-2017

SWOG launches national immunotherapy clinical trial for rare cancers

SWOG



SHARE

 PRINT  E-MAIL

PORTLAND, OR - People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It's the first federally funded immunotherapy trial devoted to rare cancers. Despite their name, rare cancers make up more than 20 percent of cancers diagnosed worldwide.

The trial is called DART, which stands for Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors. It is managed by SWOG, the cancer clinical trials group that is part of the National Cancer Institute's (NCI) National Clinical Trials Network (NCTN). The trial is sponsored by the NCI and being conducted under the NCI collaborative agreements with Bristol-Myers Squibb for ipilimumab and nivolumab.



2016 Impact Report

“ I’m pleased to present
SWOG’s inaugural annual impact report,
with highlights from 2016. Great work, team! ”

Charles D. Blanke, M.D.

Charles D. Blanke, MD, SWOG Group Chair



Leading cancer research. Together. www.swog.org

In partnership with





OREGONLIVE
The Oregonian

Chicago Tribune



HealthDay



The San Diego
Union-Tribune.




Leading cancer research. Together. www.swog.org


In partnership with



WEBSITE!!!



Leading cancer research. Together.



[About](#) [The SWOG Network](#) [News & Events](#) [Clinical Trials](#)


Public Powered Cancer Research

Today


30
open trials

1,093
member sites


208k
patients enrolled




Dr. Antoni Ribas,
SWOG investigator




Member Login




Community Oncology Research Program
A program of the National Cancer Institute of the National Institutes of Health




National Clinical Trials Network
a National Cancer Institute program

[Search](#) 

Search through clinical trials

[Meet](#) 

Attend a meeting to

[Give](#) 

Support our research by

We launched!



April 2017 SWOG Training Retreat



NCTN Operations Grant Timeline

Sept.	2017	Funding announcement
Jan.	2018	Application due
Mar.	2019	New award date





NEVER SEEN IN THE SAME ROOM TOGETHER!*

*Observation made by Dr. James Rae





Farewells & Welcomes





THE HOPE FOUNDATION

Because answers to cancers come from clinical trials

LEADERSHIP ACADEMY

Dr. Charles A. Coltman, Jr.

Fellowship

JUNIOR

- Mina Sedrak, MD, MS
City of Hope

- Timur Mitin MD, PhD
Oregon Health & Science University

MIDCAREER

- Paul Barr, MD
University of Rochester

SWOG Early Exploration and Development (SEED) Fund

- **Virginia Sun, PhD**
City of Hope
- **Nadine Housri, MD**
Rutgers Robert Wood Johnson
Medical School and theMednet
- **George V. Thomas, MD**
Oregon Health & Science University

Integrated Translational Science Center (ITSC) Pilot Awards

- **Gregory Idos, MD**
Keck School of Medicine,
University of Southern California
- **Herve Tiriac, PhD**
Cold Spring Harbor Laboratory

Integrated Translational Science Center (ITSC) Pilot Awards (cont.)

- **Alex Herrera, MD & Lu Chen, MD, PhD**
City of Hope
- **Honey Reddi, PhD & Guru Ananda, PhD**
The Jackson Laboratory
- **Paul Barr, MD**
University of Rochester

Integrated Translational Science Center (ITSC) Pilot Awards (cont.)

- **Lauren Averett Byers, MD**
MD Anderson Cancer Center
- **Paul Robson, PhD**
The Jackson Laboratory

Integrated Translational Science Center (ITSC) Pilot Awards (cont.)

- **Priyanka Sharma, MD**
University of Kansas Medical Center
- **Honey Reddi, PhD**
The Jackson Laboratory

Integrated Translational Science Center (ITSC) Pilot Awards (cont.)

- **Jill Hamilton-Reeves, PhD**
University of Kansas Medical Center
- **Mikala Egeblad, PhD**
Cold Spring Harbor Laboratory

SWOG Treatment Trial Innovations



Julie Gralow, MD
Executive Officer
Breast & Lung
Committees

SWOG Treatment Trial Innovations



Susan O'Brien, MD
Executive Officer
Leukemia, Lymphoma &
Myeloma Committees

SWOG Treatment Trial Innovations



Christopher Ryan, MD
Executive Officer
GI, GU, Melanoma &
Early Therapeutics and
Rare Cancers
Committees

Dr. Harry E. Hynes Speaker



Linda House, RN, BSN, MSM
President
Cancer Support Community

Innovations at ClinicalTrials.gov



Deborah A. Zarin, MD
Director
ClinicalTrials.gov

2017
**SEIZE THE
OPPORTUNITY**



Vote



Leading cancer research. Together. www.swog.org

In partnership with



National Clinical
Trials Network



Community Oncology
Research Program




November, 2018



Get your checkbooks ready!











SWOG



Leading cancer research. **Together.**



Leading cancer research. **Together.** www.swog.org

In partnership with

